What is the main business of Przedsiębiorstwo Zaopatrzenia Farmaceutycznego Cefarm-Lublin?

The main business activity of Przedsiębiorstwo Zaopatrzenia Farmaceutycznego Cefarm-Lublin focuses on dispensing chemist in specialised stores.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on June 12, 2001.

Where is the headquarters located?

The headquarters is located at: Al. Spółdzielczości Pracy 78, 20-147 Lublin.

Who is on the management board?

The management board includes: Bożena Helena Szymańska (President of the Management Board) and Katarzyna Ewa Nockowska Stańczak (Vice President of the Management Board).

What is the share capital?

The share capital of the company is PLN 10,532,400 (approx. $2.8 million).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What revenue was generated?

In 2025, the company generated total revenue of $102,301,481, representing an increase of 10.5% compared to 2024.

Is the company profitable?

Yes, in 2025 the company was profitable, achieving a net profit of $2,965,594, meaning the company decreased its profit by 39.7%.

What is the largest operating cost?

The largest operating cost category falls under cost of goods and materials sold. This category amounted to $78,432,339 in 2025, representing 80% of all operating expenses.

Przedsiębiorstwo Zaopatrzenia Farmaceutycznego Cefarm-LublinS.A.

Dispensing chemist in specialised stores

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2001-06-12

Share capital

10 532 400,00 PLN

Activity description

Przedsiębiorstwo Zaopatrzenia Farmaceutycznego Cefarm-Lublin S.A. is a company based in Lublin. The excerpt provides only registration details, including its KRS, tax number, and share capital amount.

Registered address

al. Spółdzielczości Pracy 78, 20-147 Lublin, Poland

Website

cefarm-lublin.pl

Electronic delivery address

AE:PL-43878-43052-BFWTU-30

Financials

Revenue history (in m)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 102.30mMedianUSD 1.75mAverageUSD 5.00m

Net profit

This companyUSD 2.97mMedianUSD 17.24kAverageUSD 82.83k

Operating costs

This companyUSD 98.45mMedianUSD 1.72mAverageUSD 4.85m

Assets

This companyUSD 30.33mMedianUSD 495.38kAverageUSD 1.71m

Industry

Bank accounts

Registered as a VAT taxpayer on 2001-01-31. Active

ING Bank Śląski
40 1050 0086 1000 0090 8117 7314
BNP Paribas Bank Polska
86 1600 1462 1806 0153 7000 0001
ING Bank Śląski
66 1050 0086 1000 0023 2551 9599

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Real estate

Type	Amount
Buildings and premises	PLN 1.4MPLN 1,442,284

MSiG notices

Publication date	Event
Dec 27, 2011	Commercial Companies Code notice
Jul 15, 2011	Merger plan
Mar 2, 2011	Bankruptcy notice
Nov 15, 2010	Merger plan

Public aid

No public aid cases recorded in the last 10 years.

Tenders

No recorded participation in tenders.

Public sector contracts

Contracts in the Central Register of Contracts: 9 · total value PLN 1,851 · public buyers: 2 · latest signed Sep 25, 2026

UNIWERSYTET MEDYCZNY IM.PIASTÓW ŚLĄSKICH WE WROCŁAWIUcontracts: 8 · PLN 1,401UNIWERSYTET MIKOŁAJA KOPERNIKA W TORUNIUcontracts: 1 · PLN 450.00

Signed	Subject	Public buyer	Value
Sep 25, 2026	zakup - płyn na skórę	UNIWERSYTET MEDYCZNY IM.PIASTÓW ŚLĄSKICH WE WROCŁAWIU	PLN 98.13
Sep 17, 2026	zakup - testy	UNIWERSYTET MEDYCZNY IM.PIASTÓW ŚLĄSKICH WE WROCŁAWIU	PLN 93.31
Sep 15, 2026	zakup preparatów do odkażania skóry	UNIWERSYTET MEDYCZNY IM.PIASTÓW ŚLĄSKICH WE WROCŁAWIU	PLN 138.86
Sep 11, 2026	zakup - glukoza	UNIWERSYTET MEDYCZNY IM.PIASTÓW ŚLĄSKICH WE WROCŁAWIU	PLN 36.96
Sep 10, 2026	zakup waty opatrunkowej	UNIWERSYTET MEDYCZNY IM.PIASTÓW ŚLĄSKICH WE WROCŁAWIU	PLN 12.94

Source: Central Register of Contracts of Public Finance Sector Units (Polish Ministry of Finance), rejestrumow.gov.pl. Company as contractor; data processed by Compabase, the Ministry of Finance is not responsible for its processed form.

National Health Fund (NFZ) contracts

Przedsiębiorstwo Zaopatrzenia Farmaceutycznego Cefarm-Lublin has been an NFZ healthcare provider since 2008. In 2026 it is performing 35 contracts with a total value of USD 1.85k. All its contracts were worth USD 24.06k in total.

NFZ contract value by year (in k USD)

Type of care	NFZ branch	Contracts	Value in 2026
Programy pilotażowe	lubelskie	5	USD 1.30k
Programy pilotażowe	warmińsko-mazurskie	1	USD 324.15
Programy pilotażowe	mazowieckie	1	USD 94.54
Programy pilotażowe	opolskie	1	USD 81.04
Programy pilotażowe	podlaskie	1	USD 54.02

Trademarks

Przedsiębiorstwo Zaopatrzenia Farmaceutycznego Cefarm-Lublin currently holds no active trademarks with the Polish Patent Office. 7 marks have expired or were not registered. The first mark was filed in 1996.

Mark	Number	Classes	Status	Protected until
gastrosol	Z.243134	0, 5	Proceedings discontinued	–
galvit(word)	Z.207837	5	Expired	–
sulfogal(word)	Z.207838	5	Expired	–
corgal(word)	Z.207839	5	Proceedings discontinued	–
retigal(word)	Z.207840	5	Expired	–

Authorized Representatives

Aleksandra Olszacka – Vice President of the Management Board

Bożena Helena Szymańska – President of the Management Board

Katarzyna Nockowska Stańczak – Vice President of the Management Board

Manner of representation

If a multi-member management board is appointed, the joint action of two members of the management board or of a member of the management board together with a commercial proxy is required for the validity of declarations of will made on behalf of the company. A commercial proxy makes declarations of will on behalf of the company jointly with a member of the management board or, if joint commercial procuration has been granted, with another commercial proxy.

Supervisory board

Andrzej Maciej Gawryś – Supervisory Board Member

Ewa Wasiak Zasada – Supervisory Board Member

Jarosław Piotr Strzecha – Supervisory Board Member

Beneficial owners

Person	Rights
Zbigniew Jacek Molenda (63)	Sprawowanie kontroli nad osobami prawnymi, którym łącznie przysługuje prawo własności więcej niż 25% ogólnej liczby udziałów lub akcji spółki
Jacek Romuald Szwajcowski (62)	Sprawowanie kontroli nad osobami prawnymi, którym łącznie przysługuje prawo własności więcej niż 25% ogólnej liczby udziałów lub akcji spółki

Competitors

	Name	Revenue	Website
	APIS Farmacjasp. z o.o.	$14,614,704.02	apisapteka.pl

Change history

Date	Event
2011-10-25	Share capital change (6,873,300.00 PLN → 10,532,400.00 PLN)
2011-02-02	Share capital change (5,878,000.00 PLN → 6,873,300.00 PLN)
2003-10-01	Address change (Bramowa 2/8, 20-111, Lublin → Al. Spółdzielczości Pracy 78, 20-147, Lublin)
2001-06-12	Entered in the register

FAQ

Last updated: 2026-07-14